SLC5A2 and heart failure: Along with emerging innovations in the area of surgical and transcatheter bioprostheses and device selection, medical therapy also evolved and implementation of pharmacological therapies of associated heart failure such as sodium-glucose cotransporter-2 inhibitors (SGLT2is) was associated with reduced all-cause death, MACE and re-hospitalization following invasive treatment of aortic stenosis [19].